Glycemic effects of continuous glucose monitoring in people with prediabetes

Glycemic effects of continuous glucose monitoring in people with prediabetes - Silence

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00040704

Enrollment

Registered

2026-06-25

Start date

2026-05-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R73.08

Interventions

Group 1: Participants in this group will receive standard of care treatment in accordance with the current Austrian Diabetes Association (ÖDG) recommendations for prediabetes. Group 2: Participants in

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) HbA1c between 5.7% and 6.4% (inclusive) 2) German Diabetes Risk Score (GDRS) >10%

Exclusion criteria

Exclusion criteria: 1) Diagnosed type 1 or type 2 diabetes mellitus 2) Active malignancy 3) Treatment with oral or intravenous glucocorticoids within the past 3 months 4) Previous treatment with a GLP-1 receptor agonist, tirzepatide, or an SGLT2 inhibitor within the past 12 months 5) Treatment with metformin or pioglitazone within the past 3 months 6) Polycystic ovary syndrome (PCOS) 7) Pregnancy 8) Weight change of more than 5% of body weight within the past 6 months 9) Overt thyroid dysfunction, clinically manifest hypercortisolism, or Addison's disease 10) Bariatric surgery within the past 6 months or planned bariatric surgery

Design outcomes

Primary

Measure	Time frame
Between-group difference in the change in Time Above Tight Range (TATR; >140 mg/dL) from blinded CGM Phase 1 to blinded CGM Phase 3 (CGM group versus the combined educational brochure and diet and physical activity counseling group). Used continuously glucose measurement systems (CGM): Dexcom G7 or FreeStyle Libre Pro iQ	—

Secondary

Measure	Time frame
Between-group differences in the change in: ? HbA1c from Visit 1 to Visit 6 ? HbA1c from Visit 1 to Visit 4 ? insulin sensitivity (HOMA-IR) from Visit 1 to Visit 6 ? indices of insulin sensitivity and beta-cell function from Visit 1 to Visit 4 ? body weight from Visit 1 to Visit 6 ? body weight from Visit 1 to Visit 4 ? Time In Tight Range (TITR; 70–140 mg/dL) from CGM Phase 1 to CGM Phase 3 ? Time Above Tight Range (TATR; >140 mg/dL) from CGM Phase 1 to CGM Phase 2 Time In Tight Range (TITR; 70–140 mg/dL) from CGM Phase 1 to CGM Phase 3	—

Measure

Time frame

Between-group differences in the change in: ? HbA1c from Visit 1 to Visit 6 ? HbA1c from Visit 1 to Visit 4 ? insulin sensitivity (HOMA-IR) from Visit 1 to Visit 6 ? indices of insulin sensitivity and beta-cell function from Visit 1 to Visit 4 ? body weight from Visit 1 to Visit 6 ? body weight from Visit 1 to Visit 4 ? Time In Tight Range (TITR; 70–140 mg/dL) from CGM Phase 1 to CGM Phase 3 ? Time Above Tight Range (TATR; >140 mg/dL) from CGM Phase 1 to CGM Phase 2 Time In Tight Range (TITR; 70–140 mg/dL) from CGM Phase 1 to CGM Phase 3

—

Countries

Austria

Contacts

Public ContactHarald Sourij

Medizinische Universität Graz, Klinische Abteilung für Endokrinologie und Diabetologie

ha.sourij@medunigraz.at+43 316 385 81310

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026